Close X
Saturday, November 30, 2024
ADVT 
National

A look at the rare blood clot condition VIPIT

Darpan News Desk The Canadian Press, 29 Mar, 2021 08:56 PM
  • A look at the rare blood clot condition VIPIT

Federal officials limited the use of Oxford-AstraZeneca's COVID-19 vaccine Monday while it announced an investigation into reported links to a rare blood clot condition known as VIPIT.

The National Advisory Committee on Immunization says the vaccine should not be used by people younger than age of 55, while Health Canada has issued guidelines around what to look for if you suspect you have had an adverse reaction.

Here’s a look at this rare condition.

WHAT IS VIPIT?

VIPIT stands for: Vaccine-Induced Prothrombotic Immune Thrombocytopenia. According to NACI, it is associated with the development of antibodies that "activate" platelets, which stimulate the formation of blood clots.

HOW DANGEROUS IS VIPIT?

The case fatality of VIPIT is approximately 40 per cent, however that may decrease with increased awareness and early treatment.

HOW COMMON IS THIS ADVERSE REACTION?

It’s not clear how common this happens after vaccination but the European Medicines Agency said March 18 it was originally believed to occur once per 1,000,000 people vaccinated with the AstraZeneca vaccine. However, a higher rate of 1 per 100,000 was reported in Germany.

WHO DOES THIS AFFECT?

So far, cases have largely been among women younger than age 55 and mostly emerged between four and 16 days after vaccination. However, a brief for Ontario’s COVID-19 advisory group notes many European countries used more of their initial AstraZeneca doses in women under age 55, which may have skewed the results.

The provincial science table experts add that VIPIT does not appear to be more common in people who have had blood clots before, have a family history of blood clots, have a low platelets, or pregnant women.

ARE THERE KNOWN CASES IN CANADA LINKED TO THE ASTRAZENECA VACCINE?

No.

WHAT ARE THE WARNING SIGNS?

Experts say to look for the following symptoms between four and 20 days after vaccination: a severe headache that does not go away; a seizure; difficulty moving part of your body; new blurry vision that does not go away; difficulty speaking; shortness of breath; chest pain; severe abdominal pain; new severe swelling, pain, or colour change of an arm or a leg.

MORE National ARTICLES

Health Canada to add warning on AstraZeneca

Health Canada to add warning on AstraZeneca
The department's chief medical adviser Dr. Supriya Sharma says the warning comes on the heels of a similar warning in Europe last week but doesn't change Health Canada's analysis that the vaccine's benefits outweigh its risks.

Health Canada to add warning on AstraZeneca

E-scooters get green light in B.C. pilot study

E-scooters get green light in B.C. pilot study
The six participating municipalities where e-scooters will soon be legal are Kelowna, Vernon, Vancouver, West Vancouver and North Vancouver city and district.

E-scooters get green light in B.C. pilot study

Urgent need for waste management in North: report

Urgent need for waste management in North: report
The marine conservation group says northern communities produce a similar level of waste to cities in the south, but have fewer ways to deal with it.

Urgent need for waste management in North: report

Advocates fear jails filling again during pandemic

Advocates fear jails filling again during pandemic
About a year after the first COVID-19 cases emerged in Ontario jails, the update by the Prison Pandemic Partnership says the risk to inmates increases when there is less space.

Advocates fear jails filling again during pandemic

O'Toole brushes off grassroots vote on climate

O'Toole brushes off grassroots vote on climate
Over the weekend, delegates to the Conservatives' policy convention voted down a resolution that would have included the line "climate change is real" in the party's official policy document.

O'Toole brushes off grassroots vote on climate

Canadians still edgy about U.S. visitors: poll

Canadians still edgy about U.S. visitors: poll
It found 70 per cent of 2,200 Canadian respondents were either very or somewhat worried about allowing cross-border travel.

Canadians still edgy about U.S. visitors: poll